New hope for tough blood cancers: testing a Two-Drug attack

This study is testing a new combination of two drugs, venetoclax and azacitidine, for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has come back or stopped responding to standard treatment. The first part of the study aims to find the safest dose, and the second part checks how well the combination works to control the disease. The goal is to see if this approach can help patients who have few other options.